like tool report far quarter
post strong result unlik other howev stock
outperform market result beat broad-bas
product line end market geographi relev
thesi pharma return posit strongest growth end
market margin would beaten consensu
one-tim tax reform bonu paid employe
guidanc also consensu think
usual left cushion undercal potenti fx
tailwind rais estim price target
quick take quarter post substanti beat
revenu ep driven core growth strength broad-
base segment comfort beat expect end
market growth also strong end year notabl pharma
grew healthcare/diagnost rebound high single-digit
growth due strength season busi demand
biomark test academic/govern saw strongest quarter
sinc high-singl digit growth geograph asia-
pacif continu lead grow high-teen
growth china year margin quarter
soft due impact acquisit one-tim
employe bonu conjunct tax reform varianc
tabl exhibit detail
guidanc manag announc guidanc revenu
project midpoint core growth
acquisit ep guidanc higher consensu
midpoint fx expect tailwind tax
rate expect bp oper margin
expect expand includ drag
patheon acquisit guidanc tabl exhibit
read-through tmo result read posit tool
player especi tmd tmo clinic trial
busi patheon also perform well think read
pharma servic space also posit
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
exclud amort acquir intang asset one-tim restructur
compani prioriti stock list
compani data secur llc estim reuter
report date estactualconsyr net expens pre-tax incom incom continu share yrseqgross bpssg bpsr bpsebitda bpsoper bpspretax bpstax bpsnet bpssegment analysisyr yrseqai total bpslss total bpssd total bpslp total bpsintra-compani segment factset compani report secur llc million except epsactualfi end decembermargin analysi thermo fisher scientif inc
priorcurrentchangepriorcurrentchangetot net expens pre-tax incom incom continu share bpssg bpsr bpsebitda bpsoper bpspretax bpstax bpsnet bpssegment analysisai total bpslss total bpssd total bpslp total bpsintra-compani segment secur llc estimatesfi end million except epsmargin life scienc tool servic diagnost
acq corecor fxconsolid oper y/ypthn would y/ynet interest expens debt financ acq assum rate increasesoth cash impact transit tax chargeweight averag share outstand due equiti offer due project time pthnshare repurchas cash flow compani press releas transcript secur llchw headwind guidanc given may guidanc given may oper oper organ revenue growth organ revenue growth bp margin expans bp margin expans adj net incom convert adj net incom convert impli tax rate tax rate compani data secur llcsourc compani data secur guidanc given may guidanc given may revenu organ revenue growth organ revenue growth oper oper margin ex-pthn average bp margin expans bp margin expans bp expans affx addit bp annual complet epsdeploy capitaldeploy capit deploy return deploy return conversionmaintain leverag ratio end yearavg leverag ratio end year tax rate tax rate compani data secur llcsourc compani data secur llc slightli higher phase thermo fisher scientif inc
thermo fisher summari data fy end decemb million except per gross oper interest incom pre-tax provis incom net non-gaap dilut share gross share analysisai total growth oper total growth oper total growth oper total growth oper segment total growth growth growth growth total net cash debt ttm debt ttm flow capit free cash compani report secur llc estimatesincom statementmargin analysischang analysi y/i life scienc tool servic diagnost
price target
price target dcf-base wacc termin noplat growth repres
ep estim risk includ deterior global macro pressur biopharma
 capital-expenditure budget declin budget government-sponsor research increas
competit and/or disrupt technolog risk associ fx volatil
think align need fastest grow end market pharma effect
cross-sel broad portfolio instrument consum servic also think
capit deploy flexibl peer due favor tax structur
waltham massachusetts-bas thermo fisher scientif inc nyse provid wide rang
analyt instrument consum research appli use life scienc industri not-
for-profit end market compani also signific provid specialti diagnost clinic
end market thermo fisher balanc revenu mix end market exposur compani
extens distribut also distinguish featur
thermo fisher oper four segment analyt instrument ai life scienc solut lss
specialti diagnost sd laboratori product servic lp ai three primari
busi chromatographi mass spectrometri chemic analysi environment process
instrument lss hold legaci bioscienc busi well life technolog
busi sd five primari busi immunodiagnost clinic diagnost microbiolog
anatom patholog healthcar market custom channel lp four primari busi
laboratori equip laboratori consum research safeti market custom channel
